Login to Your Account



Clinic Roundup


Monday, August 15, 2011
• Bio-Path Holdings Inc., of Houston, completed treatment of the first dosage cohort in the firm's Phase I trial of BP-100-1.01 (liposomal Grb-2), in development for systemic treatment of blood cancers such as acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription